세계의 경구 단백질 및 펩티드 시장 : 분자별, 약제 클래스별, 치료 영역별, 제형별 - 예측(-2030년)

The global market for oral proteins and peptides is projected to reach USD 24.00 billion by 2030 from USD 8.85 billion in 2025, at a CAGR of 22.1% during the forecast period from 2025 to 2030.

The increase in demand for oral peptides, particularly for the treatment of chronic diseases such as diabetes and central nervous system (CNS) disorders, is a major driver of growth in this market. Additionally, rising investments in research and development by key players are leading to the creation and launch of innovative oral peptides. Continuous advancements in drug delivery technologies are also contributing to market expansion.

However, the market faces challenges, including high development costs and obstacles related to formulation and stability, which hinder growth.

"The semaglutide molecule segment accounted for the largest share of the market, by molecule, in 2024."

In 2024, the semaglutide segment held the largest share of the global oral proteins and peptides market. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels and appetite. It is used to manage type 2 diabetes and obesity. Semaglutide functions by enhancing insulin secretion in response to elevated blood glucose levels, reducing glucagon release (which normally raises blood sugar), and promoting a feeling of fullness after eating, thereby helping to reduce food intake.

Oral semaglutide, marketed as RYBELSUS, is the first oral GLP-1 receptor agonist approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely utilized and recommended for managing type 2 diabetes.

"The US will continue to dominate the oral proteins and peptides market during the forecast period."

The US is the largest biopharmaceutical market in the world and a leader in biopharmaceutical research and investments. This growth is driven by several factors, including the increasing patient population suffering from infectious diseases, the rising importance of biopharmaceuticals, and the need for safe, high-quality products in the healthcare sector. There has been a significant increase in investments and funding for biomedical research from government agencies as well as pharmaceutical and biotechnology companies.

Furthermore, the early adoption of emerging technologies and alternative therapies and the widespread availability of oral proteins and peptides in the region support market expansion. The strong presence of several key market players, including Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), and Pfizer Inc. (US), is another crucial factor contributing to this growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

Research Coverage:

This research report categorizes the oral proteins and peptides market by molecule (trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and other drugs), drug class (analog of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and other drugs), therapeutic area (genetic disorders, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight, and other therapeutic areas), formulation (tablets, capsules, and oral solutions), end user (home care settings, long-term care facilities, and hospitals & specialty clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overview, products, solutions, strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, gastroenterology diseases, and kidney diseases; advancements in drug delivery technologies; patient preference and compliance for oral route of drug administration; and increasing adoption of inorganic growth strategies such as collaborations and agreements), restraints (high cost associated with drug development, contraindication of oral proteins and peptides, and stringent regulatory approval process), opportunities (robust clinical trial pipeline for oral proteins and peptides and growing demand for non-invasive and patient-friendly treatment options), and Challenges (hurdles in formulation and stability and availability of alternative therapies) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the oral proteins and peptides market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS AND REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 RESEARCH DESIGN
  • 2.1.2 SECONDARY DATA
  • 2.1.3 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
• 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024)
• 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024
• 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030
• 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing burden of chronic diseases
    • 5.2.1.2 Advancements in drug delivery technologies
    • 5.2.1.3 Higher patient compliance and preference for oral route
    • 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of drug development
    • 5.2.2.2 Contraindication of oral proteins & peptides
    • 5.2.2.3 Stringent regulatory approval process
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
    • 5.2.3.2 Growing demand for personalized medicine
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Hurdles in formulation and stability
    • 5.2.4.2 Availability of alternative therapies
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 ROLE OF RAW MATERIAL VENDORS
  • 5.3.2 ROLE OF PRODUCT PROVIDERS
  • 5.3.3 ROLE OF END USERS
  • 5.3.4 ROLE OF REGULATORY AUTHORITIES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 THREAT OF NEW ENTRANTS
  • 5.6.2 THREAT OF SUBSTITUTES
  • 5.6.3 BARGAINING POWER OF SUPPLIERS
  • 5.6.4 BARGAINING POWER OF BUYERS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.7.1 KEY STAKEHOLDERS
  • 5.7.2 BUYING CRITERIA
• 5.8 PRICING ANALYSIS
  • 5.8.1 AVERAGE SELLING PRICE, BY KEY PLAYER
  • 5.8.2 AVERAGE SELLING PRICE, BY COUNTRY & REGION
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY SCENARIO
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Transient permeation enhancers
    • 5.11.1.2 Gastrointestinal permeation enhancement technology
    • 5.11.1.3 Oral sCT (OSTORA) technology
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Peptelligence
    • 5.11.2.2 ThioMatrix
    • 5.11.2.3 Transferrin-based recombinant fusion proteins
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Oramed and Orasome
    • 5.11.3.2 Q-sphera
    • 5.11.3.3 Nanoinclusion
    • 5.11.3.4 Oleotec and Soctec
• 5.12 PIPELINE ANALYSIS
• 5.13 PATENT ANALYSIS
  • 5.13.1 METHODOLOGY
  • 5.13.2 PATENTS APPLIED AND GRANTED, 2014-2025
• 5.14 REIMBURSEMENT SCENARIO
• 5.15 KEY CONFERENCES & EVENTS, 2025-2026
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
• 5.18 IMPACT OF 2025 US TARIFFS-ORAL PROTEINS & PEPTIDES MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRIES/REGIONS
    • 5.18.4.1 US
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON MANUFACTURING INDUSTRIES
  • 5.18.6 RECOMMENDATIONS FOR MANUFACTURERS

6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE

• 6.1 INTRODUCTION
• 6.2 SEMAGLUTIDE
  • 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
• 6.3 CALCITONIN
  • 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
• 6.4 LINACLOTIDE
  • 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
• 6.5 TROFINETIDE
  • 6.5.1 FDA APPROVAL TO DRIVE MARKET
• 6.6 VOCLOSPORIN
  • 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
• 6.7 PLECANATIDE
  • 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
• 6.8 OTHER MOLECULES

7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS

• 7.1 INTRODUCTION
• 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
  • 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
• 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
  • 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
• 7.4 GUANYLATE CYCLASE-C AGONISTS
  • 7.4.1 RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET
• 7.5 GLYCINE-PROLINE-GLUTAMATE
  • 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
• 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
  • 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
• 7.7 OTHER DRUG CLASSES

8 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION

• 8.1 INTRODUCTION
• 8.2 TABLETS
  • 8.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
• 8.3 CAPSULES
  • 8.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
• 8.4 ORAL SOLUTIONS
  • 8.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH

9 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 DIABETES
  • 9.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
• 9.3 CNS DISORDERS
  • 9.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 9.4 GASTROENTEROLOGY
  • 9.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
• 9.5 GENETIC DISORDERS
  • 9.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
• 9.6 NEPHROLOGY
  • 9.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
• 9.7 OBESITY & OVERWEIGHT
  • 9.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
• 9.8 OTHER THERAPEUTIC AREAS

10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS
  • 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
• 10.4 HOSPITALS & SPECIALTY CLINICS
  • 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET

11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to hold large shares in North American and global markets
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to hold largest share of European market
  • 11.3.3 UK
    • 11.3.3.1 Strong focus on advancement of life sciences to support market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing prevalence of diabetes to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest market share in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing diabetes and obesity cases to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Regulatory approvals for GLP-1 drugs to propel market
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX
  • 12.5.1 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1.1 Stars
    • 12.5.1.2 Emerging leaders
    • 12.5.1.3 Pervasive players
    • 12.5.1.4 Participants
  • 12.5.2 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024
    • 12.5.2.1 Stars
    • 12.5.2.2 Emerging leaders
    • 12.5.2.3 Pervasive players
    • 12.5.2.4 Participants
  • 12.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.3.1 Company footprint
    • 12.5.3.2 Region footprint
    • 12.5.3.3 Molecule footprint
    • 12.5.3.4 Formulation footprint
    • 12.5.3.5 Therapeutic area footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 NOVO NORDISK A/S
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Product launches & approvals
      • 13.2.1.3.2 Deals
      • 13.2.1.3.3 Expansions
      • 13.2.1.3.4 Other developments
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Right to win
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses & competitive threats
  • 13.2.2 ABBVIE INC.
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products offered
    • 13.2.2.3 Recent developments
      • 13.2.2.3.1 Product approvals
      • 13.2.2.3.2 Deals
    • 13.2.2.4 MnM view
      • 13.2.2.4.1 Right to win
      • 13.2.2.4.2 Strategic choices
      • 13.2.2.4.3 Weaknesses & competitive threats
  • 13.2.3 PFIZER INC.
    • 13.2.3.1 Business overview
    • 13.2.3.2 Product pipeline
    • 13.2.3.3 Recent developments
      • 13.2.3.3.1 Product approvals
      • 13.2.3.3.2 Deals
      • 13.2.3.3.3 Other developments
    • 13.2.3.4 MnM view
      • 13.2.3.4.1 Right to win
      • 13.2.3.4.2 Strategic choices
      • 13.2.3.4.3 Weaknesses & competitive threats
  • 13.2.4 BAUSCH HEALTH COMPANIES INC.
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products offered
    • 13.2.4.3 Recent developments
      • 13.2.4.3.1 Product approvals
  • 13.2.5 CHIESI FARMACEUTICI S.P.A.
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products offered
    • 13.2.5.3 Recent developments
      • 13.2.5.3.1 Deals
  • 13.2.6 ACADIA PHARMACEUTICALS INC.
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products offered
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Product approvals
  • 13.2.7 AURINIA PHARMACEUTICALS INC.
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products offered
    • 13.2.7.3 Recent developments
      • 13.2.7.3.1 Product approvals
  • 13.2.8 MERCK & CO., INC.
    • 13.2.8.1 Business overview
    • 13.2.8.2 Product pipeline
    • 13.2.8.3 Recent developments
      • 13.2.8.3.1 Deals
      • 13.2.8.3.2 Other developments
  • 13.2.9 JOHNSON & JOHNSON SERVICES, INC.
    • 13.2.9.1 Business overview
    • 13.2.9.2 Product pipeline
    • 13.2.9.3 Recent developments
      • 13.2.9.3.1 Other developments
  • 13.2.10 SWK HOLDINGS
    • 13.2.10.1 Business overview
    • 13.2.10.2 Product pipeline
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Other developments
  • 13.2.11 R-PHARM JSC
    • 13.2.11.1 Business overview
    • 13.2.11.2 Products in pipeline
  • 13.2.12 ENTERA BIO LTD.
    • 13.2.12.1 Business overview
    • 13.2.12.2 Product pipeline
    • 13.2.12.3 Recent developments
      • 13.2.12.3.1 Deals
      • 13.2.12.3.2 Other developments
  • 13.2.13 PROXIMA CONCEPTS
    • 13.2.13.1 Business overview
    • 13.2.13.2 Products in pipeline
• 13.3 OTHER PLAYERS
  • 13.3.1 ASTRAZENECA PLC
  • 13.3.2 REGOR THERAPEUTICS GROUP
  • 13.3.3 TERNS PHARMACEUTICALS, INC.
  • 13.3.4 STRUCTURE THERAPEUTICS
  • 13.3.5 VIKING THERAPEUTICS
  • 13.3.6 PROTAGONIST THERAPEUTICS INC.
  • 13.3.7 RANI THERAPEUTICS
  • 13.3.8 CARMOT THERAPEUTICS, INC.
  • 13.3.9 ZEALAND PHARMA
  • 13.3.10 SCIWIND BIOSCIENCES CO., LTD.
  • 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS